Abstract:OBJECTIVE-Insulin stimulates both nitric oxide (NO)-dependent vasodilation and endothelin-1 (ET-1)-dependent vasoconstriction. However, the cellular mechanisms that control the dual vascular effects of insulin remain unclear. This study aimed to investigate the roles of the multidomain adaptor protein APPL1 in modulating vascular actions of insulin in mice and in endothelial cells.RESEARCH DESIGN AND METHODS-Both APPL1 knockout mice and APPL1 transgenic mice were generated to evaluate APPL1's physiological roles in regulating vascular reactivity and insulin signaling in endothelial cells.RESULTS-Insulin potently induced NO-dependent relaxations in mesenteric arteries of 8-week-old mice, whereas this effect of insulin was progressively impaired with ageing or upon development of obesity induced by high-fat diet. Transgenic expression of APPL1 prevented age- and obesity-induced impairment in insulin-induced vasodilation and reversed obesity-induced augmentation in insulin-evoked ET-1-dependent vasoconstriction. By contrast, genetic disruption of APPL1 shifted the effects of insulin from vasodilation to vasoconstriction. At the molecular level, insulin-elicited activation of protein kinase B (Akt) and endothelial NO synthase and production of NO were enhanced in APPL1 transgenic mice but were abrogated in APPL1 knockout mice. Conversely, insulin-induced extracellular signal-related kinase (ERK) 1/2 phosphorylation and ET-1 expression was augmented in APPL1 knockout mice but was diminished in APPL1 transgenic mice. In endothelial cells, APPL1 potentiated insulin-stimulated Akt activation by competing with the Akt inhibitor Tribbles 3 (TRB3) and suppressed ERK1/2 signaling by altering the phosphorylation status of its upstream kinase Raf-1.CONCLUSIONS-APPL1 plays a key role in coordinating the vasodilator and vasoconstrictor effects of insulin by modulating Akt-dependent NO production and ERK1/2-mediated ET-1 secretion in the endothelium. Diabetes 60:3044-3054, 2011

Genetic and pharmacological inhibition of vanin-1 activity in animal models of type 2 diabetes

Vanin 1: Its Physiological Function and Role in Diseases

Vanin-1 Is a Key Activator for Hepatic Gluconeogenesis

Mouse vanin-1 is cytoprotective for islet beta cells and regulates the development of type 1 diabetes

Vanin1 (VNN1) in chronic diseases: Future directions for targeted therapy

Analysis of vanin-1 upregulation and lipid accumulation in hepatocytes in response to a high-fat diet and free fatty acids

Visualization-Based Discovery of Vanin-1 Inhibitors for Colitis

Systemic Nanoparticle‐Mediated Delivery of Pantetheinase Vanin‐1 Regulates Lipolysis and Adiposity in Abdominal White Adipose Tissue

Brown Adipose Vanin-1 is Required for the Maintenance of Mitochondrial Homeostasis and Prevents Diet-Induced Metabolic Dysfunction

Vanadium Compounds Modulate PPARγ Activity Primarily by Increasing PPARγ Protein Levels in Mouse Insulinoma NIT-1 Cells

Is the Hypoglycemic Action of Vanadium Compounds Related to the Suppression of Feeding?

The Molecular Mechanisms and Rational Design of Anti-Diabetic Vanadium Compounds.

Synthesis, characterization and anti-diabetic therapeutic potential of novel aminophenol-derivatized nitrilotriacetic acid vanadyl complexes

Central administration of vaspin inhibits glucose production and augments hepatic insulin signaling in high-fat-diet-fed rat

The Association of the Vanin-1 N131S Variant with Blood Pressure Is Mediated by Endoplasmic Reticulum-Associated Degradation and Loss of Function

Vancomycin-Induced Modulation of Gram-Positive Gut Bacteria and Metabolites Remediates Insulin Resistance in iNOS Knockout Mice

Appl1 Counteracts Obesity-Induced Vascular Insulin Resistance And Endothelial Dysfunction By Modulating The Endothelial Production Of Nitric Oxide And Endothelin-1 In Mice

Weight-reducing, lipid-lowering and antidiabetic activities of a novel arginine vasopressin analogue acting at the V1a and V1b receptors in high-fat-fed mice

Improvement of Vascular Insulin Sensitivity by Ranolazine

Synthesis And Anti-Diabetic Activity Of New N,N-Dimethylphenylenediamine-Derivatized Nitrilotriacetic Acid Vanadyl Complexes

Vanadium compounds: New potential antidiabetic drugs